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The introduction of chemically unique groups into proteins by means
of non-natural amino acids has numerous applications in protein
engineering and functional studies. One method to achieve this
involves the utilization of a non-natural amino acid by the cell’s native
translational apparatus. Here we demonstrate that a methionine
surrogate, azidohomoalanine, is activated by the methionyl-tRNA
synthetase of Escherichia coli and replaces methionine in proteins
expressed in methionine-depleted bacterial cultures. We further
show that proteins containing azidohomoalanine can be selectively
modified in the presence of other cellular proteins by means of
Staudinger ligation with triarylphosphine reagents. Incorporation of
azide-functionalized amino acids into proteins in vivo provides op-
portunities for protein modification under native conditions and
selective labeling of proteins in the intracellular environment.
The 20 naturally occurring amino acids determine the struc-ture and chemical reactivity of the proteins that they inhabit.
Protein engineering by means of the introduction of non-natural
amino acids is an important approach to the investigation of
protein folding, structure, and function as well as the design of
novel protein reactivity (1). Indeed, incorporation of non-
natural amino acids into proteins by means of chemical methods
such as solid-phase synthesis (2), native chemical ligation (3),
and in vitro translation protocols (4, 5) has permitted charac-
terization of protein folding pathways, enzymatic mechanisms,
and ligand-receptor interactions. Recent advances in the adap-
tation of ‘‘unnatural amino acid mutagenesis’’ to cellular systems
suggests a rich future for heterologous expression of novel
proteins (6–9). At present, however, the most efficient means for
introducing non-natural amino acids into recombinant proteins
exploits the unnatural substrate tolerance of the native transla-
tional apparatus. For example, several methionine (1, Fig. 1)
analogs are used in protein biosynthesis with high efficiency,
particularly when competing methionine is eliminated by use of
a methionine auxotrophic host (10).
Replacement of methionine by analogs that possess unique
chemical reactivity offers the potential for posttranslational
protein modification. Applications include selective tagging of
proteins with probes and protein engineering for structure
function analysis (11, 12). Already the method has permitted the
incorporation of a diverse set of methionine analogs with alkyl
and unsaturated side chains (13, 14), the latter suggesting
opportunities for subsequent chemical reaction (15–17).
Toward a general method for chemical modification of proteins
in vivo, we have co-opted the biosynthetic machinery of an Esch-
erichia coli methionine auxotroph to introduce azides into proteins.
The incorporation of azide-functionalized amino acids appeared
especially attractive in light of the recent observation that azido-
sugars can be installed in cell-surface glycoproteins by means of the
sialic acid biosynthetic machinery and subsequently modified by the
Staudinger ligation (18). The ability of the azide group to survive
cellular metabolism and react selectively with phosphine reagents
under mild conditions suggested that proteins equipped with azide-
functionalized amino acids could be modified according to Scheme
1. Incorporation of azide-functionalized amino acids as methionine
surrogates may provide unique opportunities to manipulate pro-
tein–protein recognition, modify recombinant proteins, or selec-
tively label proteins in the cell.
The incorporation of methionine analogs into proteins is
controlled most stringently by the methionyl-tRNA synthetase
(MetRS) of the host. Accordingly, the rates of activation of
methionine analogs by MetRS have been shown to correlate with
their efficiencies of incorporation into target proteins (10, 14).
In this article, two azide-functionalized amino acids, azidoala-
nine (2, Fig. 1) and azidohomoalanine (3, Fig. 1), were synthe-
sized as potential methionine analogs. These two compounds
were tested as in vitro substrates for MetRS and candidates for
incorporation into proteins in vivo. The results of both in vitro
and in vivo assays confirmed 3 as an excellent methionine
surrogate. A target protein (murine dihydrofolate reductase,
mDHFR) containing 3 was modified by Staudinger ligation with
an appropriately engineered phosphine bearing an antigenic
FLAG peptide. We have further demonstrated the selectivity of
the Staudinger ligation by modifying the azide-labeled target
protein within the context of all other cellular proteins.
Materials and Methods
All chemical reagents were of analytical grade, obtained from
commercial suppliers, and used without further purification unless
otherwise noted. Reversed-phase HPLC was performed by using a
Rainin Instruments Dynamax SD-200 HPLC system with 230-nm
detection, on a Microsorb C-18 analytical column (4.6  250 mm)
at a flow rate of 1 mlmin, a semipreparative column (10  250
mm) at a flow rate of 4 mlmin, or a preparative column (25 250
mm) at a flow rate of 20 mlmin. All runs used linear gradients of
30–100% buffer B in A (Awater containing 0.1% trifluoroacetic
acid, B acetonitrile containing 0.1% trifluoroacetic acid) over 60
min. 1H and 13C NMR spectra were measured on Bruker AMX-
300, AMX-400, or DRX-500 MHz spectrometers as noted. Com-
pounds 2 (19, 20) and 3 (21) were synthesized according to
previously published procedures. Compounds 6 and 7 were syn-
thesized according to procedures described in the supporting text,
which is published on the PNAS web site, www.pnas.org.
Abbreviations: MetRS, methionyl-tRNA synthetase; mDHFR, murine dihydrofolate reduc-
tase; DMF, N,N-dimethylformamide; MALDI, matrix-assisted laser desorption ionization;
TBST, Tris-buffered saline; HRP, horseradish peroxidase.
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FLAG (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) Peptide (8). The peptide
was synthesized by using established automated protocols on a
Perkin–Elmer ABI 431 A peptide synthesizer (user-derived
cycles) using fluorenylmethoxycarbonyl (Fmoc)-Lys(Boc)-Wang
resin (Novabiochem; 0.83 mmol Lysg resin), N-Fmoc-
protected amino acids and 1,3-dicyclohexylcarbodiimide-
mediated 1-hydroxybenzotriazole (HOBt) ester activation in
1-methyl-2-pyrrolidinone. Five equivalents of N-protected
amino acid were activated for 30 min by using 10 equivalents
each of 1,3-diisopropylcarbodiimide and HOBt in N,N-
dimethylformamide (DMF). This solution was added to the resin
and shaken for 30 min. The Fmoc-protecting group of the
terminal Asp residue was removed by treatment with piperidine.
The resin was washed with DMF followed by CH2Cl2 and
transferred to a solid-phase reaction vessel for use in the
following step without further purification.
Triarylphosphine-FLAG (9). DMF (1 ml) followed by a solution of 7
(182 mg, 0.5 mmol), 1-hydroxybenzotriazole (68 mg, 0.5 mmol),
O-benzotriazol-1-yl-N,N,N,N-tetramethyluronium hexafluoro-
phosphate (190 mg, 0.5 mmol), diisopropylethylamine (87 l, 0.5
mmol) in DMF (2 ml) was added to the solid-phase reaction vessel
containing the resin-bound side-chain protected FLAG peptide
(120 mg, 0.1 mmol). The reaction vessel was agitated for 4 h at room
temperature, and then the resin was washed with DMF followed by
CH2Cl2. The washed and dried resin was treated with 95% triflu-
oroacetic acid (3 ml) for 2 h at room temperature. Filtration
afforded a solution of the crude product that was concentrated and
then purified by reversed-phase HPLC. MS (electrospray ioniza-
tion) confirmed the identity of the product with mz 680.1
(MHH).
Computation. Single-point energy ab initio calculations (Hartree-
Fock model, 6–31G* basis set) (22, 23) were performed for
methionine and for analogs 2 and 3 with fully extended side
chains. Electron density maps are shown as surfaces of electron
density 0.08 electronsau (3). Isopotential plots are represented
as surfaces where the energy of interaction between the amino
acid and a point positive charge is equal to 10 kcalmole.
Calculations were performed by using the program MACSPARTAN
(Wavefunction, Irvine, CA).
Enzyme Purification and Activation Assays. The fully active, trun-
cated form of MetRS was purified from 24 h cultures of E. coli
JM101 cells carrying the plasmid pGG3 (24) and was purified by
size-exclusion chromotography as described (25). The activation
of methionine analogs by MetRS was assayed by means of the
amino acid-dependent ATP-32P-pyrophosphate exchange reac-
tion, also as described (25–27). Specific experimental details are
provided as supporting information on the PNAS web site.
Determination of Translational Activity. The translational activity of
the methionine analogs was assayed in two bacterial hosts,
CAG18491pQE15pREP4 and CAG18491pQE15-MRS
pREP4. Procedures for preparing these hosts and assaying trans-
lational activity are described in the supporting information on the
PNAS web site.
Protein Expression and Purification. mDHFR was expressed from
1-liter cultures of CAG18491pQE15pREP4, supplemented with
either methionine or 3, using standard protocols. The mDHFR was
purified from the cell pellet by using immobilized metal affinity
chromatography. Incorporation of 3 was confirmed by amino acid
analysis, N-terminal sequencing or matrix-assisted laser desorption
ionization (MALDI) MS of the purified protein.
Chemical Modification of Purified Proteins by Staudinger Ligation.
Purified and lyophilized samples of mDHFR-Met and
mDHFR-3 were dissolved at a concentration of 0.1 mgml in
PBS at pH 7.4 containing 8 M urea. In a typical experiment, 10
l of either solution was mixed with 10 l of a solution of
triarylphosphine-FLAG (500 M in PBS, pH 7.4, 8 M urea) or
10l of the buffer without phosphine. The reactions were heated
at 47°C for 6 h to obtain maximum ligation. Standard Western
blotting procedures were then carried out to monitor the pres-
ence of all proteins bearing the N-terminal hexahistidine se-
quence as well as proteins that had reacted with the phosphine
and were therefore FLAG-labeled. Reaction mixtures were
divided in half and the two sets of reactions were subjected to
SDSPAGE in parallel. Proteins from the two gels were then
transferred to nitrocellulose membranes. One nitrocellulose
membrane was blocked with a solution of 5% dry nonfat milk in
Tris-buffered saline (TBST, 0.05 M Tris, 0.15 M NaCl, 0.05%
Tween, pH  7.4) at room temperature for 2 h. The membrane
was then washed with TBST (10 ml 2  1 min followed by 10 ml
2  30 min), and placed in a solution of anti-FLAG M2 mAb
(Sigma, 1:10 000 in TBST) for 1 h at room temperature. After
Fig. 1. Structures of methionine and the analogs tested for utility as methi-
onine surrogates. (1) Methionine, (2) azidoalanine, (3) azidohomoalanine, (4)
2-amino-5-hexynoic acid, and (5) norleucine.
Scheme 1. The Staudinger ligation between a protein containing azide
functionalized amino acid side chains and a phosphine reagent.
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the membrane was washed as before, it was incubated with
horseradish peroxidase (HRP)-rat anti-mouseIgG1 (Zymed,
1:20,000 in TBST) for 1 h at room temperature. Washing was
repeated a third time and the membrane was developed by using
Super Signal West Pico Chemiluminescent Substrate (Pierce).
The second nitrocellulose membrane was blocked with a solution
of 2.5 mgml BSA in TBST at room temperature for 2 h. The
membrane was then washed with TBST (10 ml 2 1 min followed
by 10 ml 2  30 min), and placed in a solution of India HisProbe-
HRP (Pierce, 1:5,000 in TBST) for 1 h at room temperature. After
the membrane was washed as before, it was developed by using
Super Signal West Pico Chemiluminescent Substrate (Pierce).
Chemical Modification of Proteins in Crude Cell Lysate Using the
Staudinger Ligation. Samples of CAG18491pQE 15pREP4 cul-
tures (1 ml), supplemented either with methionine or with 3,
were collected and sedimented 4 h after induction of protein
synthesis. The samples were resuspended in PBS buffer, pH 7.4
to a normalized OD600 of 15, and then frozen immediately at
20°C. DNase 1, amplification grade (GIBCO, 5 l) and RNase
H (GIBCO, 2 l) was added to the thawed cell lysate suspen-
sions. The cell lysates were incubated at room temperature for
15 min followed by 55 min at 55°C. Aliquots of cell lysate (1 l)
were diluted with PBS, pH 7.4 (9 l) and reacted with tri-
arylphosphine-FLAG under conditions similar to those de-
scribed above for the purified protein, without the addition of
urea. Western blot analysis was performed as described above.
Results and Discussion
Our initial attempts to identify azide-functionalized methionine
surrogates focused on azidoalanine (2) owing to the similarity of
its side-chain length to that of methionine and the similarity of
its side-chain geometry to that of the proven methionine surro-
gate 2-amino-5-hexynoic acid (4, Fig. 1) (27). We found, how-
ever, that 2 does not support protein synthesis in methionine-
depleted cultures of E. coli (see Fig. 3), even under conditions
where MetRS is overexpressed and the medium is supplemented
with high concentrations of 2. These conditions have been shown
previously to rescue the translational activity of methionine
analogs that have kcatKm values for activation by MetRS that are
340,000-fold lower than the kcatKm value for methionine (14).
Consistent with these observations, 2 does not support measur-
able levels of 32P-pyrophosphate exchange by MetRS in vitro
under any assay conditions investigated.
Electron density maps and isopotential surfaces of the ex-
tended side-chain structures of azidoalanine (2) and
azidohomoalanine (3) were generated to determine whether 3
might better mimic methionine. The electron density maps
(colored surfaces) and isopotential surfaces (meshes) for 2 and
3 are shown in Fig. 2; results for the known MetRS substrates,
methionine and 2-amino-5-hexynoic acid (4), are shown for
comparison. There is little similarity between the electronic
structure of the side chain of 2 and that of either methionine or
4. The side-chain isopotential surface for 2 is most highly
extended at the  position, rather than at the  position as
observed for methionine and 4. Insertion of a -methylene group
yields analog 3, in which the side-chain potential surface is most
highly extended at the  position. We proposed that this feature
of the side-chain electronic structure might contribute to acti-
vation of 3 by MetRS. Indeed, the importance of electron density
at the  position has been supported by the observation that the
thioether of the bound methionine substrate forms hydrogen
bonds with both the side chain of Tyr-260 and the backbone NH
of Leu-13 in the active site of the enzyme (28).
The rate of activation of azidohomoalanine (3) by MetRS was
determined in vitro by the ATP-32P-pyrophosphate exchange
assay. Table 1 shows the kinetic parameters determined for 3;
similar parameters measured for methionine, 2-amino-5-
hexynoic acid (4), and norleucine (5), the three amino acids
activated most efficiently by MetRS in our investigations, are
given for comparison. A kcatKm value of 1.42  103 s1M1
was obtained for activation of 3 by MetRS in vitro, indicating that
3 is a slightly better substrate than 4.
The translational activity of 3 was assessed on the basis of its
capacity to support synthesis of the target protein mDHFR in E.
coli methionine auxotroph (CAG18491pQE15pREP4) cul-
tures supplemented with the analog and depleted of methionine.
Protein expression was monitored by SDSPAGE analysis (Fig.
3). The target protein was not observed in the negative control
culture, whereas mDHFR was clearly detected in positive con-
Fig. 2. Electron density maps (colored surfaces) and negative isopotential
surfaces (meshes) for (a) methionine, (b) 2, (c) 3, and (d) 4. The electron density
maps indicate electron-rich (red) and electron-poor (blue) regions of each
molecule. For simplicity, the amino acid form is shown; this avoids represen-
tation of the highly extended isopotential surface of the carboxylate anion of
the zwitterion and facilitates comparison of side-chain electronic structures.
Fig. 3. SDSPAGE analysis of the translational activity of azide-functional-
ized amino acids. The SDSPAGE analysis was conducted on whole-cell lysates
of CAG18491pQE15pREP4 cultures, supplemented with nothing (Met),
methionine (Met), 2, or 3.
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trol cultures supplemented with methionine and in cultures
supplemented with 3. Consistent with the measured efficiency of
activation of the analog by MetRS (Table 1), 3 supported protein
synthesis in a conventional bacterial host; overexpression of
MetRS was not required. Furthermore, CAG18491pQE15
pREP4 cultures supplemented with 3 produced protein in yields
nearly identical to those observed from cultures supplemented
with methionine or 2-amino-5-hexynoic acid (4).
Azidohomoalanine-containing mDFHR (mDHFR-3) or methi-
onine-containing mDHFR (mDHFR-Met) samples were purified
and analyzed for amino acid content, identity of the N-terminal
amino acid, and changes in mass based on replacement of methi-
onine by 3. Amino acid analysis of mDHFR-3 yielded a methionine
content of 0.2 mol% compared with 3.8 mol% found in mDHFR-
Met. As 3 was unstable under the strongly acidic hydrolysis condi-
tions required for amino acid analysis, this decrease in methionine
content was taken as indirect evidence of replacement of methio-
nine by 3. On this basis, amino acid analysis indicates 95  2%
replacement of methionine.
A more direct measure of the incorporation of 3 could be
obtained from N-terminal sequencing of mDHFR-3 (Fig. 4). Un-
like the conditions required for total amino acid analysis, sequenc-
ing does not cause degradation of 3. mDHFR expressed in pQE15
is expected to retain its N-terminal methionine residue (29). As
shown in Fig. 4a, the methionine residue cleaved from the N
terminus of mDHFR-Met eluted at13.0 min. The large peaks at
14.7 min correspond to piperidylphenylthiourea (pptu), a product
of the analysis resulting from the buffer, and the small peak at18.5
min corresponds to diethylphthalate (diet), an internal standard.
When a known standard of 3 was analyzed under the same
conditions, it eluted at 11.5 min (Fig. 4b). N-terminal sequencing of
mDHFR-3 (Fig. 4c) revealed that the first amino acid site was
predominantly occupied by 3, with only a small amount of methi-
onine remaining. Integration of the two peak areas indicates 97 
2% replacement of methionine. The reduction product of 3,
2,4-diaminobutyric acid, elutes at 15.1 min; however, no such peak
was observed in the analysis of the N-terminal residue of mDHFR-3
(data not shown).
The replacement of methionine by 3 was further confirmed by
mass analysis of tryptic fragments of mDHFR-3. A mass spectrum
for a representative fragment comprising residues 153–170, with the
encoded sequence IMQEFESDTFFPEIDLGK, is given in Fig. 5.
The expected mass of the fragment containing methionine is
2,146.4 Da, whereas substitution of the single methionine by 3 yields
a fragment with a mass of 2,141.3 Da. As shown in Fig. 5, a mass
of 2,141.1 Da was observed for this fragment in the MALDI-MS
analysis of the tryptic digest of mDHFR-3, with no evidence of a
peak at 2,146.4 Da. In contrast, a peak at 2,146.4 Da was reliably
observed for the corresponding fragment obtained from tryptic
digestMALDI-MS analysis of mDHFR-Met (data not shown).
Similar results were observed for the other methionine-containing
fragments. These results strongly suggest replacement of methio-
nine by 3. However, in Fig. 5, there is clear evidence of a peak at
2,115.1 Da. This molecular mass may correspond to a peptide
fragment in which the azide had been converted to an amine,
resulting in a mass loss of 26 Da. Similar mass losses are observed
in the additional tryptic fragments of mDHFR-3 (data not shown).
This finding suggests that the intracellular reducing potential of E.
coli may be sufficient to cause partial reduction of 3 to 2,4-
diaminobutyric acid (DABA), either before or after it is incorpo-
rated into mDHFR-3. Because DABA was not observed at the
N-terminal residue, it is possible that this position is uniquely
shielded from reduction relative to the rest of the protein. Future
experiments using strains of E. coli that have been engineered to
maintain a more oxidizing environment within the cytoplasm could
circumvent this problem (30).
Having expressed an azide-modified form of mDHFR we next
investigated the reactivity of this protein with a phosphine in the
Staudinger ligation. We designed triarylphosphine-FLAG con-
jugate 9 for selective reaction with mDHFR at sites substituted
with 3 (Scheme 2). The phosphine moiety (7) possesses three aryl
substituents to limit air oxidation. One of the aryl rings is
derivatized with a methyl ester ortho to the phosphorus atom,
providing an electrophilic trap for the nucleophilic nitrogen in
Table 1. Comparison of kinetic parameters for 3 with those for
methionine and methionine analogs 4 and 5
Analog
kcatKm
(s1M1)
kcatKm
(rel)*
Relative protein
yield (%)†
Met 5.47  101 1 100
3 1.42  103 1390 100
4 1.16  103 1500 100
5 5.22  104 11,050 57
*Relative to kcatKm for Met.
†Yield of mDHFR relative to that obtained from Met-supplemented cultures of
E. coli strain CAG18491pQE15pREP4 (35 mgliter).
Fig. 4. N-terminal sequencing results indicating occupancy of the initiator site
in mDHFR produced in bacterial cultures supplemented with 3. N-terminal resi-
dues are shown for (a) DHFR-Met, (b) the free amino acid 3, and (c) DHFR-3,
as determined by Edman degradation. pptu, piperidylphenylthiourea; diet,
diethylphthalate.
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the aza-ylide formed on reaction with azides. This type of
phosphine has been successfully used in several model
Staudinger ligations as well as those described for labeling cell
surface azide-bearing sialic acids with a biotinylated phosphine
(18). The addition of a FLAG peptide to 7 enhanced water
solubility (crucial for biological applications) and provided an
epitope for detection with anti-FLAG antibodies.
The synthesis depicted in Scheme 2a began with the Sandmeyer
reaction of commercially available 1-methyl-2-aminoterephthalate
to form the aryl-iodide 6. This compound was reacted with diphe-
nylphosphine by means of a palladium-mediated cross-coupling
reaction to provide phosphine 7. Standard methods of solid-phase
peptide synthesis provided the side-chain-protected FLAG peptide
bound to Wang resin at the C terminus and a free amine at the N
terminus (Scheme 2b). The resin-bound peptide was coupled to 7
and the crude product was simultaneously deprotected and cleaved
from the resin with trifluoroacetic acid. Purification by reversed-
phase HPLC provided the final product 9.
Purified mDHFR-Met and mDHFR-3 each were reacted with
250 M 9 or with buffer alone as a negative control. The products
of those four reactions were separated by SDSPAGE and exam-
ined for the presence of the FLAG epitope (Fig. 6a). In a parallel
experiment, the products of the four reactions were examined for
the presence of the hexahistidine sequence of mDHFR, to ensure
that the FLAG peptide was ligated to mDHFR and that protein
degradation was not taking place under the reaction conditions
(Fig. 6b). It is evident from Fig. 6a that Staudinger ligation
proceeded when both mDHFR-3 and 9 were present in the reaction
(lane 1). Untreated mDHFR-3 did not show any anti-FLAG
immunoreactivity (Fig. 6a, lane 2). Likewise, when mDHFR-Met
was treated with 9 or with buffer alone, no FLAG peptide was
associated with the protein (Fig. 6a, lanes 3 and 4). A similar
Western blot using the anti-His6 antibody confirmed that FLAG
immunoreactivity was coincident with mDHFR (Fig. 6b, lane 1).
The results shown in Fig. 6b also demonstrate that possible side
reactions such as proteolysis are not occurring, because lanes 2–4
each show a single immunoreactive protein at the appropriate
molecular mass for mDHFR.
Complete ligation of triarylphosphine-FLAG (1.3 kDa) at
eight possible positions in mDHFR-3 is expected to produce a
shift in molar mass of 10.4 kDa relative to the unligated
protein. As shown in lanes 1 of Fig. 6, however, a distribution of
molecular masses was observed, indicating modification of
mDHFR-3 by triarylphosphine-FLAG (9) at fewer than the eight
possible sites. The resolution of SDSPAGE analysis is insuffi-
cient to assign an exact number of triarylphosphine-FLAG
conjugates to each band, and each band may represent more than
one ligation product. Given these limitations, it appears that at
least five different ligation products are formed based on the
Western blot analysis.
To optimize the conditions for Staudinger ligation of
mDHFR-3, a range of temperatures, triarylphosphine-FLAG (9)
concentrations, and reaction times was studied. Reaction for 6 h
with 250 M 9 at 47°C was found to be optimal. Longer reaction
times, higher concentrations of 9, and higher temperatures did
not produce additional ligation products, nor a more uniform
product distribution.
The incomplete modification of all eight sites in mDHFR-3 may
be the result of several factors. Reduction of the azide within 3 to
the amine would preclude ligation at any residue where this has
taken place. As described previously, some reduction was suggested
from tryptic digestMALDI-MS analysis of mDHFR-3. It is also
possible that the quantitative yields obtained from reaction of
azides with triarylphosphine reagents demonstrated in model re-
actions (18) do not apply within the context of the protein.
Despite the product heterogeneity observed upon ligation of
mDHFR-3 with 9, these results confirmed the high selectivity of the
Staudinger ligation. To place even higher demands on selectivity,
we performed the reaction on crude cell lysates containing either
mDHFR-Met or mDHFR-3. Samples of each cell lysate mixture
were reacted with or without 9 and examined for the presence of
both FLAG (Fig. 6c) and hexahistidine immunoreactivity (Fig. 6d).
Similar to results using purified protein, FLAG immunoreactivity
depended on the presence of both mDHFR-3 and 9 (Fig. 6c, lane
1). Neither ligation nor degradation occurred in the control reac-
Fig. 5. Mass spectrometric analysis of a tryptic fragment of mDHFR-3. The
tryptic digest of mDHFR-3 was analyzed by MALDI-MS; results are shown for
a fragment with an expected mass of 2,146.4 Da. The observed peak at a mass
of 2,141.1 Da is consistent with that expected for the fragment in which 3
replaces methionine. The peak at 2,115.1 Da may correspond to a fragment in
which 3 has been reduced to 2,4-diaminobutyric acid.
Scheme 2. Synthesis of triarylphosphine-FLAG conjugate 9.
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tions, as shown by the consistent appearance of hexahistidine
immunoreactivity (Fig. 6d). The impressive selectivity of the reac-
tion underscores its potential to label target azide-bearing proteins
among a multitude of cellular components.
Conclusions
Our results demonstrate that azidohomoalanine (3) is recognized as
a methionine surrogate by the translational apparatus of E. coli.
Incorporation of other azidoamino acids into proteins in vivo may
also be possible. Arylazides, for example, would provide opportu-
nities for photoactivated modification of proteins as well as
Staudinger ligations. Furthermore, these studies indicate that trans-
lationally active amino acid analogs can be rationally designed based
on side-chain features important in analog recognition by the
appropriate aminoacyl-tRNA synthetase (aaRS). Computational
methods that can determine energies for the binding of various
non-natural amino acids to an aaRS may facilitate the rational
design of new translationally active analogs.
The chemoselective modification of mDHFR-3 demonstrated
herein is an example of a route for selective modification of
recombinant proteins. The selectivity of the Staudinger ligation
even within a complex cell lysate mixture suggests the exciting
prospect of intracellular applications. If the reaction were to
proceed similarly within an intact cell, functionalities such as spin
labels, fluorophores, and radiolabels may be appended to a phos-
phine and delivered to an azide-labeled protein of interest installed
in a cell. Given the concise structure of the azide, it is possible that
azide-substituted versions of other amino acids will be tolerated by
the translational machinery. In this case, the Staudinger ligation
may prove to be a highly versatile tool for posttranslational protein
engineering.
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